JACOBS LEVY EQUITY MANAGEMENT, INC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 171 filers reported holding BRIDGEBIO PHARMA INC in Q2 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q4 2022$9,784,004
-18.0%
1,283,990
+7.0%
0.07%
-29.8%
Q3 2022$11,929,000
+1830.3%
1,200,078
+1662.6%
0.09%
+1780.0%
Q2 2022$618,000
+204.4%
68,085
+1155.7%
0.01%
+150.0%
Q3 2020$203,000
-61.0%
5,422
-66.1%
0.00%
-66.7%
Q2 2020$521,00015,9880.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q2 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders